Department of Psychiatry, Stanford University School of Medicine and Stanford Cancer Center Psychosocial Oncology Program, Stanford, California.
Department of Psychiatry, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida.
Transplant Cell Ther. 2024 Sep;30(9S):S493-S512. doi: 10.1016/j.jtct.2024.05.024.
Among the potential complications of allogeneic hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD) is common and associated with significant physical and psychosocial symptom burden. Despite substantial advances in GVHD treatment, the global immune suppression that frequently accompanies GVHD treatment also contributes to high rates of physical and emotional suffering and mortality. The complex manifestations of GVHD and its treatment warrant a multidisciplinary team-based approach to managing patients' multi-organ system comorbidities. A biobehavioral framework can enhance our understanding of the complex association between medications, physical symptoms, and psychosocial distress in patients with GVHD. Hence, for this perspective, we highlight the importance of addressing both the physical and psychosocial needs experienced by patients with GVHD and provide guidance on how to approach and manage those symptoms and concerns as part of comprehensive cancer care.
在异基因造血干细胞移植（HSCT）的潜在并发症中，移植物抗宿主病（GVHD）很常见，并且与明显的身体和心理社会症状负担有关。尽管在 GVHD 治疗方面取得了重大进展，但 GVHD 治疗中经常伴随的全球免疫抑制也导致了身体和情绪痛苦以及死亡率的高发生率。GVHD 的复杂表现及其治疗需要多学科团队方法来管理患者的多器官系统合并症。生物行为框架可以增强我们对 GVHD 患者药物、身体症状和心理社会困扰之间复杂关联的理解。因此，对于这种观点，我们强调了满足 GVHD 患者身体和心理社会需求的重要性，并提供了关于如何作为综合癌症护理的一部分来处理这些症状和问题的指导。
